News

Bispecific Antibody Plus EGFR Inhibitor in EGFR-Mutant Lung Cancer

IL-2–Sparing Tumor-Infiltrating Lymphocyte Cell Therapy for Melanoma

CXCR1/2 Inhibitor Plus Pembrolizumab in Metastatic Melanoma: Early-Phase Trial Results

Easing the Effects of T-DXd: Electronic Symptom Tracking Tested in PRO-DUCE Trial

Neoadjuvant Immunotherapy for Squamous Cell Skin Cancer

Lifileucel Plus Pembrolizumab Active in Melanoma Setting in Phase II Trial

Quality-of-Life Data Support Pembrolizumab’s Role in Early-Stage NSCLC

Novel Monoclonal Antibody and Chemotherapy Under Study in Nonmelanoma Skin Cancer

Vaccine Plus Immunotherapies Under Investigation in Advanced Melanoma

Comparing Therapies for Transplant-Ineligible Patients Newly Diagnosed With Myeloma

Palbociclib-Based Therapy for HER2-Positive and PAM50 Luminal Advanced Breast Cancer

mRNA Vaccine Under Study in Merkel Cell Carcinoma

Antibody-Drug Conjugate ARX788 Under Study in HER2-Positive Breast Cancer

Advanced Cutaneous Squamous Cell Carcinoma: Predicting Response to Immune Checkpoint Inhibitor Therapy

$600K Grant Awarded to Wistar Researcher to Study Impact of Microbial Genes on Immunotherapy Response in Melanoma

Amivantamab Plus Lazertinib in High-Risk Subgroups With Advanced NSCLC

ASCO 2024: Targeted Triplet for Leptomeningeal Metastasis in HER2-Positive Breast Cancer

Neoadjuvant Use of Pembrolizumab in Locally Advanced Squamous Cell Skin Cancer

ASCO 2024: Study Analysis Focuses on Nodal Status With Neoadjuvant Nivolumab in Stage III NSCLC

ASCO 2024: Impact of Discontinuing Immunotherapy After Response in Merkel Cell Carcinoma

ASCO 2024: Phase I Findings on Novel Bispecific Protein for Cutaneous Melanoma

ASCO 2024: Quadruplet vs Triplet Regimen for Newly Diagnosed Transplant-Ineligible Multiple Myeloma

ASCO 2024: Triplet Regimen Under Study in High-Risk, Resectable Melanoma

ASCO 2024: DREAMM-7 Subgroup Analyses Support BVd in Resistant Myeloma

ASCO 2024: New Antibody-Drug Conjugate Under Study in First Line for Advanced NSCLC

ASCO 2024: Adjuvant Use of Avelumab in High Risk, Early-Stage Triple-Negative Breast Cancer

ASCO 2024: KEYNOTE-942 Evaluates mRNA-4157 Plus Pembrolizumab in Resected Melanoma

ASCO 2024: Quality of Life With Neoadjuvant Immunotherapy for Stage III Melanoma

ASCO 2024: MUC1 Vaccine Plus Neoadjuvant Chemotherapy for Early-Stage Breast Cancer

ASCO 2024: Use of Tilsotolimod Plus Ipilimumab vs Ipilimumab Alone in Advanced Melanoma

ASCO 2024: Can Idecabtagene Vicleucel Improve Outcomes in Extramedullary Multiple Myeloma?

ASCO 2024: Updated IMpower010 Survival Analysis of Atezolizumab in PD-L1–Positive NSCLC

ASCO 2024: Immunotherapy for Ulcer-Related Squamous Cell Skin Cancer

ASCO 2024: Results From EV-202 of Enfortumab Vedotin in Breast Cancer Cohorts

ASCO 2024: BRAF and MEK Inhibitors Plus Immunotherapy for BRAF V600E/K–Mutated Melanoma

ASCO 2024: Taxane-Free First-Line Regimen for Advanced HER2-Positive Breast Cancer

ASCO 2024: Subcutaneous vs Intravenous Amivantamab Combined With Lazertinib in NSCLC

ASCO 2024: Early Results From EVOKE-01 of Sacituzumab Govitecan in Metastatic NSCLC

ASCO 2024: Risk-Adapted Surgical De-escalation for Resectable Squamous Cell Carcinoma

ASCO 2024: Novel Antibody-Drug Conjugate Under Study in Advanced Triple-Negative Breast Cancer

ASCO 2024: Triplet Immunotherapy Regimen Focus of Study in Advanced Melanoma

ASCO 2024: Is Belantamab Mafodotin Making a Comeback in the DREAMM-8 Myeloma Trial?

ASCO 2024: DESTINY-Breast06 Update on T-DXd vs Chemotherapy in Metastatic Breast Cancer

ASCO 2024: Phase III Trial Evaluates Neoadjuvant Immunotherapy for Stage III Melanoma

Adding Perioperative Nivolumab to Neoadjuvant Chemotherapy for Resectable NSCLC

STK11 Mutations and Immunotherapeutic Efficacy in NSCLC